299 related articles for article (PubMed ID: 31995639)
1. Cardioprotection in right heart failure.
Boengler K; Schlüter KD; Schermuly RT; Schulz R
Br J Pharmacol; 2020 Dec; 177(23):5413-5431. PubMed ID: 31995639
[TBL] [Abstract][Full Text] [Related]
2. Myocardial ischaemia reperfusion injury and cardioprotection in the presence of sensory neuropathy: Therapeutic options.
Bencsik P; Gömöri K; Szabados T; Sántha P; Helyes Z; Jancsó G; Ferdinandy P; Görbe A
Br J Pharmacol; 2020 Dec; 177(23):5336-5356. PubMed ID: 32059259
[TBL] [Abstract][Full Text] [Related]
3. Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols.
Penna C; Andreadou I; Aragno M; Beauloye C; Bertrand L; Lazou A; Falcão-Pires I; Bell R; Zuurbier CJ; Pagliaro P; Hausenloy DJ
Br J Pharmacol; 2020 Dec; 177(23):5312-5335. PubMed ID: 31985828
[TBL] [Abstract][Full Text] [Related]
4. Hyperlipidaemia and cardioprotection: Animal models for translational studies.
Andreadou I; Schulz R; Badimon L; Adameová A; Kleinbongard P; Lecour S; Nikolaou PE; Falcão-Pires I; Vilahur G; Woudberg N; Heusch G; Ferdinandy P
Br J Pharmacol; 2020 Dec; 177(23):5287-5311. PubMed ID: 31769007
[TBL] [Abstract][Full Text] [Related]
5. Ageing, sex, and cardioprotection.
Ruiz-Meana M; Boengler K; Garcia-Dorado D; Hausenloy DJ; Kaambre T; Kararigas G; Perrino C; Schulz R; Ytrehus K
Br J Pharmacol; 2020 Dec; 177(23):5270-5286. PubMed ID: 31863453
[TBL] [Abstract][Full Text] [Related]
6. Effect of hypercholesterolaemia on myocardial function, ischaemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning.
Andreadou I; Iliodromitis EK; Lazou A; Görbe A; Giricz Z; Schulz R; Ferdinandy P
Br J Pharmacol; 2017 Jun; 174(12):1555-1569. PubMed ID: 28060997
[TBL] [Abstract][Full Text] [Related]
7. Co-morbidities and co-medications as confounders of cardioprotection-Does it matter in the clinical setting?
Kleinbongard P; Bøtker HE; Ovize M; Hausenloy DJ; Heusch G
Br J Pharmacol; 2020 Dec; 177(23):5252-5269. PubMed ID: 31430831
[TBL] [Abstract][Full Text] [Related]
8. Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.
Korkmaz-Icöz S; Radovits T; Szabó G
Br J Pharmacol; 2018 Jan; 175(2):223-231. PubMed ID: 28213937
[TBL] [Abstract][Full Text] [Related]
9. The role of chemokines and chemokine receptors in pulmonary arterial hypertension.
Mamazhakypov A; Viswanathan G; Lawrie A; Schermuly RT; Rajagopal S
Br J Pharmacol; 2021 Jan; 178(1):72-89. PubMed ID: 31399998
[TBL] [Abstract][Full Text] [Related]
10. Influence of mental stress and environmental toxins on circadian clocks: Implications for redox regulation of the heart and cardioprotection.
Li H; Kilgallen AB; Münzel T; Wolf E; Lecour S; Schulz R; Daiber A; Van Laake LW
Br J Pharmacol; 2020 Dec; 177(23):5393-5412. PubMed ID: 31833063
[TBL] [Abstract][Full Text] [Related]
11. Right heart failure in pulmonary hypertension: Diagnosis and new perspectives on vascular and direct right ventricular treatment.
Tello K; Seeger W; Naeije R; Vanderpool R; Ghofrani HA; Richter M; Tedford RJ; Bogaard HJ
Br J Pharmacol; 2021 Jan; 178(1):90-107. PubMed ID: 31517994
[TBL] [Abstract][Full Text] [Related]
12. Right ventricular hypertrophy and failure abolish cardioprotection by ischaemic pre-conditioning.
Andersen A; Povlsen JA; Bøtker HE; Nielsen-Kudsk JE
Eur J Heart Fail; 2013 Nov; 15(11):1208-14. PubMed ID: 23818649
[TBL] [Abstract][Full Text] [Related]
13. sGC-cGMP-PKG pathway stimulation protects the healthy but not the failing right ventricle of rats against ischemia and reperfusion injury.
Andersen A; Povlsen JA; Johnsen J; Jespersen NR; Bøtker HE; Nielsen-Kudsk JE
Int J Cardiol; 2016 Nov; 223():674-680. PubMed ID: 27568988
[TBL] [Abstract][Full Text] [Related]
14. Chronic inflammatory diseases, myocardial function and cardioprotection.
Lazou A; Ikonomidis I; Bartekova M; Benedek T; Makavos G; Palioura D; Cabrera Fuentes H; Andreadou I
Br J Pharmacol; 2020 Dec; 177(23):5357-5374. PubMed ID: 31943142
[TBL] [Abstract][Full Text] [Related]
15. The role of mitochondrial dynamics in cardiovascular diseases.
Forte M; Schirone L; Ameri P; Basso C; Catalucci D; Modica J; Chimenti C; Crotti L; Frati G; Rubattu S; Schiattarella GG; Torella D; Perrino C; Indolfi C; Sciarretta S;
Br J Pharmacol; 2021 May; 178(10):2060-2076. PubMed ID: 32294237
[TBL] [Abstract][Full Text] [Related]
16. Three-dimensional electron microscopy techniques for unravelling mitochondrial dysfunction in heart failure and identification of new pharmacological targets.
Daghistani HM; Rajab BS; Kitmitto A
Br J Pharmacol; 2019 Nov; 176(22):4340-4359. PubMed ID: 30225980
[TBL] [Abstract][Full Text] [Related]
17. Preconditioning and postconditioning: underlying mechanisms and clinical application.
Hausenloy DJ; Yellon DM
Atherosclerosis; 2009 Jun; 204(2):334-41. PubMed ID: 19081095
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-induced pulmonary hypertension-Utilizing experiments of nature.
Gassmann M; Cowburn A; Gu H; Li J; Rodriguez M; Babicheva A; Jain PP; Xiong M; Gassmann NN; Yuan JX; Wilkins MR; Zhao L
Br J Pharmacol; 2021 Jan; 178(1):121-131. PubMed ID: 32464698
[TBL] [Abstract][Full Text] [Related]
19. Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction.
Weiss A; Boehm M; Egemnazarov B; Grimminger F; Savai Pullamsetti S; Kwapiszewska G; Schermuly RT
Br J Pharmacol; 2021 Jan; 178(1):31-53. PubMed ID: 31709514
[TBL] [Abstract][Full Text] [Related]
20. Exploring mitochondrial cholesterol signalling for therapeutic intervention in neurological conditions.
Desai R; Campanella M
Br J Pharmacol; 2019 Nov; 176(22):4284-4292. PubMed ID: 31077345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
